Strength Seen in Anthera (ANTH): Stock Soars 25% – Tale of the Tape

February 11, 2015 Technicals 0

Zacks

Anthera Pharmaceuticals, Inc. (ANTH) was a big mover last session with its shares surging 25% on the day. The upside was owing to the company’s successful completion of an interim analysis of its Phase 3 trial (CHABLIS-SC1) of blisibimod in patients with Systemic Lupus Erythematosus. This development led to far more shares changing hands yesterday than in a normal session. The move breaks the recent trend of the company as the stock is now trading above the past one month’s volatile price range of $1.99 to $2.60.

This biopharmaceutical company has seen no estimate revision in the last 30 days. The Zacks Consensus Estimate has also remained unchanged over the same period. Yesterday’s price action is encouraging though, so make sure to keep a close watch on this firm in the near future.

Anthera currently has a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%.

A better-ranked bio-med/gene stock is Affymetrix Inc. (AFFX) sporting a Zacks Rank #1 (Strong Buy).

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

To read this article on Zacks.com click here.

Zacks Investment Research

Be the first to comment

Leave a Reply